| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Dihydropyrimidine Dehydrogenase, DPYD Full Gene Sequencing, Varies
MessageSendout, Mayo test code: DPYDZ
Test Code
LAB5210603
Alias/See Also
5-Fluorouracil
5-FU Capecitabine
DPD
DPYD
DPYDZ
5-FU Capecitabine
DPD
DPYD
DPYDZ
CPT Codes
81232
Preferred Specimen
Collect 3 mL whole blood in a lavendar EDTA tube
Minimum Volume
0.45 mL whole blood
Other Acceptable Specimens
Saliva collected in a Saliva Swab Collection Kit (T786)
Instructions
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
Specimen preferred to arrive within 96 hours of collection.
2. Send whole blood specimen in original tube. Do not aliquot.
Specimen preferred to arrive within 96 hours of collection.
Transport Container
Original lavender EDTA tube
Transport Temperature
Ambient
Specimen Stability
Ambient: 9 days
Refrigerated: 30 days
Refrigerated: 30 days
Methodology
Polymerase Chain Reaction (PCR) followed by DNA Sequence Analysis
FDA Status
Approved
Setup Schedule
Monday through Friday
Report Available
5 to 10 days
Limitations
Samples may contain donor DNA if obtained from patients who received non-leukocyte reduced blood transfusions or allogeneic hematopoietic stem cell transplantation. Results from samples obtained under these circumstances may not accurately reflect the recipient's genotype. For individuals who have received blood transfusions, the genotype usually reverts to that of the recipient within 6 weeks. For individuals who have received allogeneic hematopoietic stem cell transplantation, a pretransplant DNA specimen is recommended for testing.
DPYD genetic test results in patients who have undergone liver transplantation may not accurately reflect the patient's dihydropyrimidine dehydrogenase (DPD) status.
Rare genetic variants in the primer binding regions can affect the testing, and ultimately, the genotype assessment made, including false-negative or false-positive results.
Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. Large deletions or rearrangements are not detected by this assay, and these may affect DPD protein expression and fluoropyrimidine-related adverse effects or tumor response.
Sometimes a genetic alteration of unknown significance may be identified. In this case, testing of appropriate family members may be useful to determine pathogenicity of the alteration.
This test is not designed to provide specific dosing or drug selection recommendations and is to be used as an aid to clinical decision making only. Drug-label guidance should be used when dosing patients with medications regardless of the predicted phenotype.
DPYD genetic test results in patients who have undergone liver transplantation may not accurately reflect the patient's dihydropyrimidine dehydrogenase (DPD) status.
Rare genetic variants in the primer binding regions can affect the testing, and ultimately, the genotype assessment made, including false-negative or false-positive results.
Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. Large deletions or rearrangements are not detected by this assay, and these may affect DPD protein expression and fluoropyrimidine-related adverse effects or tumor response.
Sometimes a genetic alteration of unknown significance may be identified. In this case, testing of appropriate family members may be useful to determine pathogenicity of the alteration.
This test is not designed to provide specific dosing or drug selection recommendations and is to be used as an aid to clinical decision making only. Drug-label guidance should be used when dosing patients with medications regardless of the predicted phenotype.
Reference Range
Included with report
Performing Laboratory
Mayo Clinic Laboratories, Rochester, Minnesota
Additional Information
Dihydropyrimidine Dehydrogenase, DPYD Full Gene Sequencing, Varies
